On September 12, HeartFlow Inc rose 8.02% in regular trading, trading at $49.265 per share, with turnover of approximately $52.09 million.

On the news front, UBS recently initiated coverage on HeartFlow Inc with a Neutral rating and a $55 price target, implying further upside from the current trading level. Notably, the UBS target price stands significantly above the prior analyst consensus mean target of $36.62, sending a positive signal to the market and boosting investor sentiment.

The bullish catalyst comes amid a strong fundamental backdrop. In Q2, HeartFlow reported a non-GAAP loss of $0.07 per share, beating the consensus estimate of a $0.13 loss by 46%. Revenue grew to $64.1 million from $43.4 million a year earlier, also surpassing the $56.6 million estimate. The company raised its full-year revenue guidance to $246 million–$250 million, well above the prior FactSet consensus of $230.1 million. Multiple brokerages have initiated coverage in recent months, including Baird at Outperform with a $34 target and William Blair at Outperform, reflecting growing institutional attention toward this AI-driven coronary artery disease diagnostics company.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)